|
The proportion of children receiving a second dose of the MMR vaccine is still below the threshold to stop viral transmission.
|
 |
|
Eydenzelt is subjecting Eylea to further biosimilar erosion, though Regeneron hopes to offset this with two new approvals for Eylea HD.
|
|
|
Armlupeg is indicated to reduce infection risk, specifically febrile neutropenia, in non-myeloid cancer patients.
|
|
|
If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.
|
|
|
With an eye on 2026, the healthcare editorial team reflects on key takeaways and trends from recent pharma conferences.
|
|
